FindTrial
Sign In

Delirium treatment at the surgical ward (DELTa S) Treatment of delirium: rivastigmine or haloperidol as primary treatment for delirium in elderly patients with a fractured hip. A randomized placebo-controlled study.

Delirium treatment at the surgical ward (DELTa S) Treatment of delirium: rivastigmine or haloperidol as primary treatment for delirium in elderly patients with a fractured hip. A randomized placebo-controlled study.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON29441
Enrollment
100
Registered
2005-11-25
Start date
2006-01-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium treatment on a surgical ward.

Interventions

Haloperidol or rivastigmine for the treatment of delirium.

Sponsors

trial medication sponsored by Novartis
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with a fractured hip, admitted on a surgical ward.

Exclusion criteria

Exclusion criteria: Already use of Haloperidol/Rivastigmine/Donepezil/Galantamine.

Design outcomes

Primary

MeasureTime frame
Length of delirium.—

Secondary

MeasureTime frame
1. Length of stay hospital; 2. Severity of delirium; 3. Functional outcome 3,6,13 weeks after delirium; 4. Need of escape medication; 5. Cognition; 6. Adverse events.—

Contacts

Public ContactR.J.A. Wensen, van

Jeroen Bosch Hospital, Department of Surgery, P.O Box 90153

r.v.wensen@jbz.nl+31 (0)73 6992708

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)